Pharmacokinetics and Safety of Extended-release Ranolazine in Korean and White Healthy Subjects

• Published in: Clinical therapeutics 2021-03, Vol.43 (3), p.526-534.e4
• Main Authors: Yoo, Hyounggyoon, Lee, Sang Won, Yoon, Deok Yong, Yoon, Seo Hyun, Cho, Joo-Youn, Yu, Kyung-Sang, Jang, In-Jin, Lee, SeungHwan
• Format: Article
• Language: English
• Subjects: Angina pectoris; Confidence intervals; Dosage; Ethnicity; Exposure; Korean subjects; Minority & ethnic groups; Pharmacokinetics; Pharmacology; Plasma; ranolazine; Safety; Statistical analysis; Variance analysis
• ISSN: 0149-2918; 1879-114X
• DOI: 10.1016/j.clinthera.2021.01.005

Ranolazine, an inhibitor of late inward sodium current, is an antianginal agent. In this study, the pharmacokinetic (PK) properties and tolerability of single- and multiple-dose ranolazine were compared between healthy Korean and white subjects. An open-label, ascending single- and multiple-dose study was conducted with healthy male Korean and white subjects. Subjects were administered 375–750 mg of ranolazine once in a single-dose and twice daily in multiple-dose based on their dose groups. Blood samples for the PK assessment were collected up to 48 h after dosing. The geometric mean ratio and its 90% confidence interval in Korean to white subjects for Cmax, Cmax,ss, AUClast, and AUC0–12h,ss of ranolazine were calculated. A population PK analysis was also performed. Safety profiles were assessed throughout the study. A total of 70 Korean and 48 white subjects completed the study. Ranolazine exposure was similar between Korean and white subjects in all dose groups; however, ranolazine exposure at 750 mg was observed to increase by up to 29% in Korean subjects compared with that in white subjects. On the basis of previous studies, these differences in ranolazine exposure between the 2 ethnic groups may not result in any clinically significant difference. Furthermore, ethnicity was not significantly correlated with the PK properties of ranolazine in the ranolazine PK model. In addition, no significant difference was found in the safety profile of ranolazine between the 2 ethnic groups. The PK properties of ranolazine had no clinically significant difference, and no difference was found in the safety profiles of ranolazine between Korean and white subjects. It is anticipated that ranolazine can be administered in Korean subjects without dose adjustment. ClinicalTrials.gov identifier: NCT02817932. •Ranolazine, an angina agent has not been studied in Korean subjects.•Ranolazine showed no clinically significant ethnic pharmacokinetic differences.•Ranolazine showed similar safety profile between Korean and Caucasian.